US Senator Calls Out Big Pharma Over Improper Inhaler Patents
AstraZeneca, Boehringer Ingelheim, GSK And Teva Urged To Remove Patents From Orange Book
US Senator Baldwin’s letters to four inhaler manufacturers come after the FTC challenged their patents last year, but the companies rejected patent amendment claims.
You may also be interested in...
In its latest batch of product-specific guidances, the FDA released multiple new and revised guidances on inhalers, including several on GSK’s products such as Relenza and the Ellipta trio.
The Indian generics manufacturer has reported a nearly 300% year-on-year growth in profits in Q3, as it starts to see the impact of its Spiriva generic’s launch in the US.
Product hopping, patent manipulation, patient assistance programs and pay-for-delay are all points of inquiry in Sen. Bernie Sanders and fellow HELP Democrats latest drug pricing investigation, which targets pricey inhalers that have gone decades without generic competition.